Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 217-090-4 | CAS number: 1738-25-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
3-dimethylaminopropionitrile cause urinary bladder And kidney damage after ingestion
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LOAEL
- 350 mg/kg bw/day
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEC
- 100 mg/m³
Additional information
There are limited oral and inhalative data available to assess the toxic potential of 3-dimethylaminopropionitrile after repeated dosing.
Oral
In a subacute study with male Sprague-Dawley rats, five animals received 350 mg/kg bw for 14 days (Mumtaz et al.1991).
Animal weight, water consumption, and urine volume were recorded every 24 h . Morphologic and histologic studies on liver, bladder, and kidney were performed at the end of the 2-wk period. However relevant study parameters (i.e. hematology, clinical chemistry, histology) and a post exposure period are missing. Results of morphologicand histologic studies were not reported. Bladder lesions were found and reported in cocurrent 3 days sudies including same concetrations. A decrease in animal weight, water consumption, and urine volume lead to a LOAEL of 350 mg/kg bw, a NOAEL was not identifiable. In a shortly described study with limited reliability, rats were treated twice on one day with 0.31 or 0.62 mL/kg bw, corresponding to ca. 267 or 533 mg/kg bw (density 0.86 g/mL), and sacrificed after three days (Jaeger et al. 1980, Val. 4). At both doses acute macroscopic and histological changes (urinary bladder) occured. The changes consisted of massive transmural edema, acute ulcers and inflammation and occasionally hemorrhagic necrosis of the bladder wall.
Inhalation
A 14-day screening study with rats was conducted with the objective to detect neuropathological changes; due to missing test parameters no AEC was identifiable in this study (BG Chemie 1989). Groups of 5 Wistar rats per sex were exposed to 0 ; 0.01 ; 0.1 and 1 mg/L, respectively, for 6 hours per workday for two weeks before sacrifice. Mortality, clinical signs, body weight, urinalysis, gross necropsy and histology were studied and therefore some relevant study parameters (i.e. hematology, clinical chemistry) and a post exposure period are missing. At the highest concentration of 1 mg/L toxic effects (unspecific clinical signs, retarded body weight gain) were observed. However, neither urine parameters nor pathological/ histopathological examinations showed a significant substance-related effect. The NOEC is carefully considered to be 0.1 mg/L.
Repeated dose toxicity: via oral route - systemic effects
(target organ) urogenital: kidneys; urogenital: urinary bladder
Justification for classification or non-classification
According to the available information, there is a need to classify 3-dimethylaminopropionitrile for its toxic potential after repeated dosing.
Based on CLP, a classification & labelling with STOT RE Cat. 2 (GHS) appears justified and is therefore applied for DMAPN CAS No. 1738 -25 -6.
The underlying reason is that based on CLP (3.9.2.6) there is Human evidence available, however effects levels cannot be quantified and the effect is at least partly reversible according to the literature reviewed and as assessed by the German MAK commission (2003). A comparable exposure situation is not to be expected und e the conditions the substance is being handled at the workplace today, in addition.
More important, and justifying the CLP-exemption for classification & labelling as STOT RE Cat. 2 instead of Cat. 1 (based on Human evidence), the effects levels observed in animal studies are outside the guidance values for classification & labelling. In the available 14 day studies, no effects have been observed on bladder function at the high dose = 1 mg/l/6h/day. With respect to oral exposure, this is comparable to doses where effects on bladder function etc. have been reported.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.